subscribe to our newsletter sign up
Uro-oncology company sold to international pharmaceutical group
Clayton Utz, AMP challenged by ASIC over failure to produce documents:

Uro-oncology company sold to international pharmaceutical group

Uro-oncology company sold to international pharmaceutical group

K&L Gates had advised TOLMAR International Limited on the sale of its Australian subsidiary.

Firm: K&L Gates (TOLMAR International Limited)

Deal: TOLMAR International Limited has been advised on the sale of 100 per cent of its shares in its Australian subsidiary TOLMAR Australia Pty Ltd to Mundipharma.

Value: Undisclosed

Area: M&A

Key players: The K&L Gates legal team was led by Melbourne M&A partner John Mann, and included Sydney tax partner Betsy-Ann Howe, senior associate Danielle Larkin and lawyer Rachel McNally.

Deal significance: TOLMAR Australia Pty Ltd (TOLMAR) was established in 2013. It is described as a specialised uro-oncology and men’s health organisation, providing medicines and support to those with advanced prostate cancer.

In addition, the company holds exclusive rights to distribute oncology pharmaceutical products “ELIGARD” and “BiELIGARD” in Australia, according to a statement by K&L Gates.

Meanwhile, the purchaser - Mundipharma - is an international pharmaceutical group.

Commenting on the significance of the transaction, K&L Gates partner John Mann noted TOLMAR’s reputation within its industry.

“TOLMAR has a reputation for delivering high-quality products to the market,” Mr Mann said.

“The sale of TOLMAR complements Mundipharma’s existing product range and will ensure product access for patients and healthcare professionals well into the future.

“We are pleased to have helped them achieve a successful result.”

Recommended by Spike Native Network